Can immune cells help islet transplants work better for diabetes?

NCT ID NCT05973734

ENROLLING_BY_INVITATION Disease control Sponsor: Stanford University Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial tests whether adding immune cells—either the patient's own regulatory T cells or donor bone marrow cells—to a standard islet transplant can improve blood sugar control in people with brittle type 1 diabetes. About 24 adults aged 18 to 70 will receive one of these cell infusions alongside the transplant. The main goals are safety and feasibility, with secondary goals including better HbA1c, fewer severe low blood sugar events, and reduced insulin needs.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: regulatory T cells or donor vertebral bone marrow
What this could lead to: If successful, this could improve blood sugar control and reduce severe hypoglycemia in people with brittle type 1 diabetes, potentially lowering insulin needs.
What could go wrong: This is a very early phase 1 trial with only 24 participants, so results may not apply broadly. There are risks of serious infusion reactions or transplant-related complications.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ISLET TRANSPLANTATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

type 1 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ISLET TRANSPLANTATION

Contacts and locations

Locations

Stanford University

Palo Alto, California, 94305, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.